Missed Aditya Bardia, MD 's Tweetorial on treating HER2-low mBC: 2L and beyond? No worries! It is now available on-demand: ow.ly/qBz250RiMSO
Explore patient case discussions covering ESR1 and PIK3CA co-mutations, TRAE management, and post-2L treatment options. Don't miss
Erman Akkus ACS Journal Cancer I can't get full text access. Do they look at PIK3CA mutation status? nejm.org/doi/full/10.10…
Dr Ihab Suliman. دكتور ايهاب فتحي سليمان CLOVES syndrome (Congenital Lipomatous Overgrowth Vascular malformations Epidermal Nevis, Scoliosis/ Spinal/Skeletal abnormalities) occurs due to gain of function mutation of PIK3CA gene.
It’s a part of PIK3CA Related Overgrowth Syndrome (PROS) spectrum.
Very less survival
#TumorBoardTuesday Margaret Gatti-Mays MD MPH FACP Integrity CE, LLC Paolo Tarantino Rebecca Shatsky, MD Erika Hamilton, MD Charu Aggarwal, MD, MPH, FASCO Aditya Bardia, MD Hope Rugo Maryam Lustberg MD MPH Eleonora Teplinsky, MD Stephanie Graff, MD, FACP, FASCO Jane Lowe Meisel, MD Jennifer Litton Dr Sarah Sammons Ilana Schlam Nancy Lin, MD Yara Abdou, MD Arielle Medford, MD Laura Huppert, MD Joannie M. Ivory, MD, MSPH, MHS Heather McArthur, MD, MPH 27/28 #TumorBoardTuesday
🔁 Back to the Case:
😔PD after 4 months on SG (ADC ☝️> ADC✌️). 🔺LN
🧬NGS testing on liver: PIK3CA, ERBB2, and ‼️TMB 79 mut/mb. MSS.
➡️Started on 4L pembrolizumab for TMB-High, response ongoing
#PubSaludMurcia Preventing alpelisib-related hyperglycaemia in HR+/HER2-/ PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial Área 1 Arrixaca doi.org/10.1016/j.ecli…
Erman Akkus ACS Journal Cancer My pleasure. Around the time it was published I tried to integrate it into our reports. I was told we should not put aspirin on our NGS reports for PIK3CA activating mutation + CRC. Obviously the study stuck in my memory.
Yakup Ergün OncoAlert eClinicalMedicine – The Lancet Discovery Science Interesting findings in the METALLICA study on the use of metformin to curb alpelisib-induced hyperglycemia in HR+/HER2−/PIK3CA-mutated breast cancer. It underscores the importance of proactive metabolic management in targeted cancer therapy. Further nuanced reviews and insights
Rebecca Shatsky, MD Yakup Ergün OncoAlert eClinicalMedicine – The Lancet Discovery Science I'm glad I don't have the PIK3CA mutation! I hope that one or more of these other drugs become available and that they are less toxic with better side effect profile: ncbi.nlm.nih.gov/pmc/articles/P…
